EPS miss of 75% vs consensus will pressure the stock near-term. Monitor analyst reactions and any cost control initiatives. The DAYBUE growth and guidance reaffirmation provide a floor, but rising SG&A is a concern.
Price Chart
Executive Summary
Acadia Pharmaceuticals Q1 2026 earnings missed consensus sharply with EPS of $0.02 (vs $0.08 est) and revenue of $268M (vs $280.3M est). Revenue grew 10% YoY, but EPS fell 82% YoY due to a 36% surge in SG&A expenses. Full-year 2026 guidance was reaffirmed, providing some stability.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP revenue $268M, up 10% YoY from $244M
- Q1 2026 GAAP diluted EPS $0.02, down 82% from $0.11 YoY
- SG&A expense $171M, up 36% from $126M YoY, driving operating loss
- DAYBUE net sales $101M (+20% YoY), NUPLAZID $167M (+5% GAAP, +6% adjusted)
- Full-year 2026 guidance reaffirmed: revenue $1.22-1.28B
Financial Impact
EPS miss of 75% vs consensus ($0.02 actual vs $0.08 est); revenue miss of ~4%
Risk Factors
- Continued SG&A cost inflation without corresponding revenue acceleration
- Remlifanserin Phase 2 data risk (readout Aug-Oct 2026)
- IRA rebate adjustments may cause further earnings volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-209253 |
| Document: acad-20260506.htm | 0001193125-26-209253 |
| Document: 0001193125-26-209253-index-headers.html | 0001193125-26-209253 |
| Document: 0001193125-26-209253-index.html | 0001193125-26-209253 |
| Document: 0001193125-26-209253.txt | 0001193125-26-209253 |
| 8-K Data (Synthetic) | 0001193125-26-209253 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $27.52 $26.40 | ▼ −4.09% | ▼ −4.19% | $19.95 (−27.51%) |
Aug 17, 2026 6w ago | Institutional Cluster | $29.01 $29.65 | ▲ +2.21% | ▲ +3.40% | $19.95 (−31.23%) |
Aug 7, 2026 7w ago | Insider Cluster | $29.39 $29.01 | ▼ −1.29% | ▼ −1.25% | $19.95 (−32.12%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.39 $21.60 | ▼ −0.98% | ▼ −0.55% | $19.95 (+6.73%) |
May 6, 2026 21w ago | 8-K | $22.56 $22.18 | ▲ +1.68% | ▲ +3.19% | $19.95 (+11.57%) |
May 4, 2026 21w ago | Insider Cluster | $22.19 $21.80 | ▼ −1.76% | ▼ −4.69% | $19.95 (−10.09%) |
Mar 25, 2026 27w ago | Insider Cluster | $22.01 $22.32 | ▲ +1.41% | ▲ +1.65% | $19.95 (−9.36%) |
Mar 5, 2026 30w ago | 8-K | $22.40 $21.27 | ▼ −5.04% | ▼ −2.81% | $19.95 (−10.94%) |
Feb 25, 2026 31w ago | 8-K | $24.64 $22.40 | ▼ −9.09% | ▼ −7.96% | $19.95 (−19.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access